Piper Sandler Reiterates Overweight Rating for Health Catalyst (NASDAQ:HCAT)

Piper Sandler reissued their overweight rating on shares of Health Catalyst (NASDAQ:HCAT) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $12.00 price target on the stock, up from their previous price target of $11.00.

A number of other equities research analysts also recently weighed in on the company. Royal Bank of Canada raised their price target on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Evercore ISI boosted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Stephens raised their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Finally, Citigroup upped their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $11.79.

Health Catalyst Stock Performance

Shares of HCAT opened at $8.65 on Tuesday. The company has a market capitalization of $526.34 million, a PE ratio of -6.41 and a beta of 1.32. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The company’s 50 day moving average price is $8.12 and its 200 day moving average price is $7.31. Health Catalyst has a 52 week low of $5.42 and a 52 week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter in the prior year, the firm earned ($0.22) earnings per share. The company’s revenue was up 3.5% on a year-over-year basis. Research analysts expect that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Activity at Health Catalyst

In other news, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at approximately $1,062,018.64. This trade represents a 5.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,068 shares of company stock worth $257,555 in the last 90 days. 2.50% of the stock is owned by company insiders.

Institutional Trading of Health Catalyst

Hedge funds have recently modified their holdings of the company. Quest Partners LLC bought a new stake in shares of Health Catalyst during the third quarter valued at approximately $34,000. Nisa Investment Advisors LLC lifted its position in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the period. Quarry LP boosted its stake in Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares in the last quarter. nVerses Capital LLC bought a new stake in Health Catalyst in the 3rd quarter valued at $59,000. Finally, Perfromance Wealth Partners LLC acquired a new position in shares of Health Catalyst in the 2nd quarter valued at $64,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.